Sign In
10 Jun 2008 10:12
10 June 2008
Colostrinin™/CogniSure™ Sales Update - Estimated Market Value* $2.2m in First Half of 2008
ReGen Therapeutics Plc ('ReGen') announces that it is providing guidance on the market value of Colostrinin™/CogniSure™ ordered by Metagenics Inc., its licensee and distribution partner for the USA, Australasian and Canadian markets, in the first half of 2008. Based on the number of kilos ordered by Metagenics, and assuming all are sold, ReGen estimates that the market value of these orders would be approximately $2.2m
Percy Lomax, Executive Chairman of ReGen commented "We are delighted with the progress that Colostrinin™/CogniSure™ has made since its launch into the professional market. We believe this is a substantial achievement given that it is less than a year since the product was first launched in Australia and it has only been on the US market for eight months.
For further information, please contact:
Percy Lomax
ReGen Therapeutics Plc
Tel: 020 7153 4920
Roland Cornish/Felicity Geidt
Beaumont Cornish Limited
Tel: 020 7628 3396
David Scott/Nick Bealer
Alexander David
Tel: 020 7448 9800
Adrian Duffield/Jon Davies
College Hill Associates
Tel: 020 7457 2020
Note:
*Market value is the total sales value at the price per unit paid by the consumer.
Follow the stocks
